Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Accured Expenses (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Change in Accured Expenses for 5 consecutive years, with -$79000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 106.11% year-over-year to -$79000.0, compared with a TTM value of -$2.0 million through Dec 2025, down 46.33%, and an annual FY2025 reading of -$2.0 million, down 46.33% over the prior year.
  • Change in Accured Expenses was -$79000.0 for Q4 2025 at Aligos Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.1 million in Q2 2021 and bottomed at -$12.4 million in Q2 2022.
  • Average Change in Accured Expenses over 5 years is -$637900.0, with a median of -$39000.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses plummeted 93800.0% in 2023, then soared 6322.73% in 2025.
  • Year by year, Change in Accured Expenses stood at -$134000.0 in 2021, then surged by 1882.09% to $2.4 million in 2022, then soared by 55.07% to $3.7 million in 2023, then plummeted by 65.08% to $1.3 million in 2024, then crashed by 106.11% to -$79000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for ALGS at -$79000.0 in Q4 2025, $1.4 million in Q3 2025, and $1.4 million in Q2 2025.